ISOLATED ORGAN PERFUSION COMBINATION THERAPY OF CANCER
    1.
    发明申请
    ISOLATED ORGAN PERFUSION COMBINATION THERAPY OF CANCER 审中-公开
    分离的器官灌注组合治疗癌症

    公开(公告)号:WO2007082742A1

    公开(公告)日:2007-07-26

    申请号:PCT/EP2007/000408

    申请日:2007-01-18

    IPC分类号: A61K38/17 A61P35/00

    摘要: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and/or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.

    摘要翻译: 本发明涉及用于治疗肿瘤和肿瘤转移的组合疗法,其包括将整联蛋白配体,优选整联蛋白拮抗剂,以及当与所述配体如化学治疗剂一起施用时具有协同疗效的共同治疗剂或治疗形式, /或放射治疗,分离器官灌注。 治疗导致每个单独治疗剂对肿瘤细胞增殖的抑制作用的协同增加潜力,产生比通过单独施用单独组分发现的更有效的治疗。

    ISOLATED ORGAN PERFUSION COMBINATION THERAPY OF CANCER
    6.
    发明申请
    ISOLATED ORGAN PERFUSION COMBINATION THERAPY OF CANCER 审中-公开
    分离的器官灌注组合治疗癌症

    公开(公告)号:WO2007082742A8

    公开(公告)日:2008-05-15

    申请号:PCT/EP2007000408

    申请日:2007-01-18

    IPC分类号: A61K38/17 A61P35/00

    摘要: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and/or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.

    摘要翻译: 本发明涉及用于治疗肿瘤和肿瘤转移的组合疗法,其包括将整联蛋白配体,优选整联蛋白拮抗剂,以及当与所述配体如化学治疗剂一起施用时具有协同效力的共同治疗剂或治疗形式, /或放射治疗,分离器官灌注。 治疗导致每个单独治疗剂对肿瘤细胞增殖的抑制作用的协同增加潜力,产生比通过单独施用单独组分发现的更有效的治疗。